Related references
Note: Only part of the references are listed.Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia
Ana Flavia Tiburcio Ribeiro et al.
BLOOD (2012)
Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia
Guido Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
TET2 Mutations in Acute Myeloid Leukemia (AML): Results From a Comprehensive Genetic and Clinical Analysis of the AML Study Group
Verena I. Gaidzik et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia
K. H. Metzeler et al.
LEUKEMIA (2012)
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Jay P. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity
Erdogan Taskesen et al.
BLOOD (2011)
Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers
Veronika Rockova et al.
BLOOD (2011)
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category
Klaus H. Metzeler et al.
BLOOD (2011)
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Mark Levis et al.
BLOOD (2011)
FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype
Katharina Wagner et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Prognostic Significance of ASXL1 Mutations in Patients With Myelodysplastic Syndromes
Felicitas Thol et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prognostic Importance of Histone Methyltransferase MLL5 Expression in Acute Myeloid Leukemia
Frederik Damm et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia
Felicitas Thol et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group
Jan Kroenke et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
RUNX1 Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group
Verena I. Gaidzik et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
Klaus H. Metzeler et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Therapeutic Advances in Acute Myeloid Leukemia
Alan Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Heiko Becker et al.
BLOOD (2010)
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Patrick S. Ward et al.
CANCER CELL (2010)
Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group
Nicolas Boissel et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Single Nucleotide Polymorphism in the Mutational Hotspot of WT1 Predicts a Favorable Outcome in Patients With Cytogenetically Normal Acute Myeloid Leukemia
Frederik Damm et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study
Heiko Becker et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
High EVI1 Expression Predicts Outcome in Younger Adult Patients With Acute Myeloid Leukemia and Is Associated With Distinct Cytogenetic Abnormalities
Stefan Groeschel et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Impact of IDH1 R132 Mutations and an IDH1 Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic Factor
Katharina Wagner et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic Significance of Expression of a Single MicroRNA, miR-181a, in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
Sebastian Schwind et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
Guido Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
Peter Paschka et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic Significance of CEBPA Mutations in a Large Cohort of Younger Adult Patients With Acute Myeloid Leukemia: Impact of Double CEBPA Mutations and the Interaction With FLT3 and NPM1 Mutations
Claire L. Green et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
DNMT3A Mutations in Acute Myeloid Leukemia.
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Array-based genomic resequencing of human leukemia
Y. Yamashita et al.
ONCOGENE (2010)
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
William Blum et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
IDH mutations in glioma and acute myeloid leukemia
Lenny Dang et al.
TRENDS IN MOLECULAR MEDICINE (2010)
Impaired function of primitive hematopoietic cells in mice lacking the Mixed-Lineage-Leukemia homolog Mll5
Vikas Madan et al.
BLOOD (2009)
Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group
Verena Ingeborg Gaidzik et al.
BLOOD (2009)
Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome
Sabine Kayser et al.
BLOOD (2009)
High Id1 expression is associated with poor prognosis in 237 patients with acute myeloid leukemia
Ruoping Tang et al.
BLOOD (2009)
AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations
Jih-Luh Tang et al.
BLOOD (2009)
Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia
Veronique Gelsi-Boyer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Treatment of acute myeloid leukemia
Elihu H. Estey
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B
Richard F. Schlenk et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Prognostic Importance of MN1 Transcript Levels, and Biologic Insights From MN1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
Christian Langer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Dysregulation of the C/EBPα Differentiation Pathway in Human Cancer
Steffen Koschmieder et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
ERG Expression Is an Independent Prognostic Factor and Allows Refined Risk Stratification in Cytogenetically Normal Acute Myeloid Leukemia: A Comprehensive Analysis of ERG, MN1, and BAALC Transcript Levels Using Oligonucleotide Microarrays
Klaus H. Metzeler et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Mutations of ASXL1 gene in myeloproliferative neoplasms
N. Carbuccia et al.
LEUKEMIA (2009)
Acquired mutations in TET2 are common in myelodysplastic syndromes
Saskia M. C. Langemeijer et al.
NATURE GENETICS (2009)
Mutation in TET2 in Myeloid Cancers
Francois Delhommeau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
Elaine R. Mardis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia:: a Cancer and Leukemia Group B (CALGB) study
Christian Langer et al.
BLOOD (2008)
High EVI1 levels predict adverse outcome in acute myeloid leukemia:: prevalence of EVI1 overexpression. and chromosome 3q26 abnormalities underestimated
Sanne Lugthart et al.
BLOOD (2008)
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia
Ramiro Garzon et al.
BLOOD (2008)
Molecular characterization of acute myeloid leukemia
Konstanze Doehner et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Mutation of the Wilms' Tumor 1 Gene Is a Poor Prognostic Factor Associated With Chemotherapy Resistance in Normal Karyotype Acute Myeloid Leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party
Priya Virappane et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study
Peter Paschka et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study
Guido Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine:: A Cancer and Leukemia Group B study
Andreas Neubauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype
C. Haferlach et al.
LEUKEMIA (2008)
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
Richard F. Schlenk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
MicroRNA expression in cytogenetically normal acute myeloid leukemia
Guido Marcucci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Distinct microRNA expression profiles in acute myeloid leukemia with common translocations
Zejuan Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin
Ramiro Garzon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications
Susan P. Whitman et al.
BLOOD (2008)
MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia
Shuangli Mi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia
Adam J. Mead et al.
BLOOD (2007)
High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia:: A Cancer and Leukemia Group B study
Guido Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase III randomized trial of intensive induction and consolidation chemotherapy ± oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old
G. Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication:: a Cancer and Leukemia Group B study
Susan P. Whitman et al.
BLOOD (2007)
High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics
Michael Heuser et al.
BLOOD (2006)
The many facets of the Wilms' tumour gene, WT1
Peter Hohenstein et al.
HUMAN MOLECULAR GENETICS (2006)
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype
S Schnittger et al.
BLOOD (2005)
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics:: interaction with other gene mutations
K Döhner et al.
BLOOD (2005)
Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis
M Yanada et al.
LEUKEMIA (2005)
The MLL partial tandem duplication:: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy
SP Whitman et al.
BLOOD (2005)
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.
B Falini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The 1,25(OH)(2)D-3-regulated transcription factor MN1 stimulates vitamin D receptor-mediated transcription and inhibits osteoblastic cell proliferation
ALM Sutton et al.
MOLECULAR ENDOCRINOLOGY (2005)
CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics:: Prognostic relevance and analysis of cooperating mutations
S Fröhling et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
MicroRNAs: Genomics, biogenesis, mechanism, and function
DP Bartel
CELL (2004)
ETS transcription factors: Possible targets for cancer therapy
T Oikawa
CANCER SCIENCE (2004)
Mechanisms of disease: Gene silencing in cancer in association with promoter hypermethylation
JG Herman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics:: a Cancer and Leukemia Group B Study
CD Baldus et al.
BLOOD (2003)
The MN1 oncoprotein synergizes with coactivators RAC3 and p300 in RAR-RXR-mediated transcription
KHM van Wely et al.
ONCOGENE (2003)
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia:: results from Cancer and Leukemia Group B (CALGB 8461)
JC Byrd et al.
BLOOD (2002)
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics:: a study of the AML Study Group Ulm
S Fröhling et al.
BLOOD (2002)
Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics:: A study of the acute myeloid leukemia study group Ulm
K Döhner et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia:: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
S Schnittger et al.
BLOOD (2002)
The role of MLL in hematopoiesis and leukemia
P Ernst et al.
CURRENT OPINION IN HEMATOLOGY (2002)
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis
C Thiede et al.
BLOOD (2002)
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
PD Kottaridis et al.
BLOOD (2001)
Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia
S Mizuno et al.
BLOOD (2001)
Share Paper
